Study aims and goal: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington’s Disease. No. of study participants and sites: The study plans to enrol participants from 2 sites in Australia and New Zealand. For further information see the clinical trial registration. *EHDN endorsement: The EHDN endorses protocols it finds […]
Important Dates
no event
Latest News
Novartis Pharmaceuticals INVEST-HD study endorsed* by EHDN
Study aims and goal: Phase III study to investigate the efficacy, safety and tolerability of Votoplam in participants with Huntington’s Disease. No. of study participants and sites: It is planned to enrol 770 participants globally. The number of sites and countries is still to be determined. For further information see the clinical trial registration. *EHDN […]
CHDI’s 21st Annual Huntington’s Disease Therapeutics Conference
… to be held February 23 through 26, 2026 in Palm Springs, California. The emphasis of this conference is preclinical research relevant to drug development for HD, including the latest advances in understanding HD pathophysiology, current and emerging biomarkers, and novel therapeutic approaches. Conference Details […]
EHDN Platform Meeting (Webinar) –
Is it time to target inflammation in Huntington’s disease?
Evidence supports inflammation playing a role in Huntington’s disease pathogenesis. The mutant huntingtin protein disrupts immune cell function, centrally and peripherally. Long before symptom onset, activated microglia and astrocytes can be detected and levels of pro-inflammatory molecules like IL-6 and TNF-α are found increased in CSF and plasma. Far from being just a byproduct of […]
FUNDING OPPORTUNITY: European Partnership for BrainHealth Call 2
Multinational research grants for neurodegenerative disorders including Huntington’s disease | Up to 3 years funding | 33 participating countries | Pre-proposal deadline: March 10, 2026 Further details → https://www.brainhealth-partnership.eu/ […]
Professor Sarah Tabrizi – One of ten people who helped shape science in 2025
Congratulations to Professor Sarah Tabrizi (University College London), an investigator on the EHDN-endorsed uniQure AMT-130 gene therapy trial, on the exceptional achievement of being named one of Nature’s 10 – an annual list recognising individuals who shaped science in 2025. Read the feature here: https://www.nature.com/immersive/d41586-025-03848-1/index.html […]
uniQure topline results: unpacking the outcome so far – update
EHDN Platform Meeting in collaboration with HDYO and EHA on uniQure topline results: Unpacking the outcomes so far The EHDN Platform Meeting took place on Tuesday, 18th November 2025. Recording is available below and on EHDN YouTube Full report summarising the meeting is available HERE Statement from EHDN Chairs on uniQure’s Topline Results Since the […]
EHDN Imaging Working Group (iWG) newsletter – edition 4
The EHDN Imaging Working Group has now produced its third newsletter. The newsletter provides relevant updates on imaging studies, research advancements, and innovative techniques in neuroimaging. Imaging Working Group (iWG) NEWSLETTER Edition 4 | October 2025 […]
EHDN Newsletter – 56th edition
The EHDN newsletter (archive) aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists. It appears three times a year (March 1, July 1, Nov 1). To receive EHDN news going forward, please subscribe to the EHDN news at the […]
EHDN Platform Meeting in collaboration with HDYO and EHA – UniQure topline results: unpacking the outcome so far
The Platform Meeting will take place on Tuesday, 18th of November, at 17:00-18:30 CET. The presentations by Prof. Anne Rosser and Prof. Sarah Tabrizi will be followed by an expert panel discussion. The event will be chaired by Prof. Åsa Petersén. All are very welcome to attend and follow this highly anticipated conversation. We […]